FAQ  /  Women's Hormone Health

Darrell Wilcox, MD · Medical Director

Is My Hair Thinning Because of My Testosterone Dose?

Quick Answer

Not necessarily, and it's worth ruling out the alternatives before lowering a dose that may be helping everything else. Thyroid function, iron stores, chronic stress, and estrogen decline are all common, correctable causes of hair shedding that get overlooked once a hormone is the newest thing in the picture. When thinning genuinely is androgen-driven, it's about your individual follicle sensitivity to DHT, not simply your testosterone level, which is why two people on the same dose can have very different results.

A real workup checks the overlooked causes first, then looks at the androgen picture if the pattern still fits. Bring it up with your care team rather than adjusting your dose on your own.

On this page

Two Different Things Can Look Like the Same Problem

Diffuse shedding across the whole scalp and pattern thinning at the part or crown come from different mechanisms and need different workups. Diffuse shedding, called telogen effluvium, is usually a delayed reaction, two to three months out, to something else entirely: illness, a crash diet, a major stressor, or a hormonal shift. Pattern thinning is driven by androgen exposure at the follicle itself. You can have both at once, which is exactly why "just lower the dose" doesn't always fix it.

What Usually Gets Overlooked First

Before testosterone gets the blame, it's worth ruling out:

  • Thyroid function, including free T3, not just TSH. TSH can sit inside the normal range while tissues still aren't getting enough.
  • Ferritin, your iron storage marker. Hair follicles are metabolically demanding, and low stores can trigger shedding well before you're anemic on a standard CBC.
  • Chronic stress and cortisol, with the same two to three month lag that makes the connection easy to miss.
  • Estrogen decline, since estrogen helps prolong the growth phase of the hair cycle independent of testosterone.
  • Zinc, vitamin D, and protein intake, inexpensive to check and correct.

None of this rules out DHT as a contributor. It means DHT shouldn't be the first, or only, explanation reached for.

Why Follicle Sensitivity, Not Dose, Usually Explains the Difference Between People

Testosterone itself doesn't act on the follicle directly. A local enzyme, 5-alpha-reductase, converts it to DHT right at the follicle, and DHT binds the androgen receptor far more potently. Genetic variation in the androgen receptor gene is the best-established driver of pattern hair loss (Hillmer AM et al., 2005, PMID: 15902657), though that study was conducted in men and applies here as receptor biology, not female-specific data. A related enzyme gene, SRD5A1, has been linked to androgen sensitivity in women with PCOS (Goodarzi MO et al., 2006, PMID: 16849416), though a direct test of that same gene specifically in female pattern hair loss found no significant association (Redler S et al., 2012, PMID: 22509838). No study has yet validated a genetic test that predicts your personal DHT threshold in advance. What the evidence does support: individual sensitivity is real and dose-independent, which is a reasonable explanation for why outcomes vary between people on the same regimen, even without a test that identifies who's more sensitive beforehand.

A blood DHT level is usually not a useful test here. It reflects conversion happening throughout the body, not at your follicle specifically, and it can't tell you how sensitive your receptor is regardless of the number. A scalp exam, sometimes with trichoscopy, is what actually distinguishes a diffuse process from a patterned one.

How to Actually Find Out What's Driving It

A real workup starts by ruling the overlooked causes in or out: TSH alongside free T3, ferritin, vitamin D, recent stressors, and diet. If those are clear and the pattern looks androgenetic rather than diffuse, DHEA-S, free and total testosterone, and SHBG characterize the androgen picture, though they won't predict follicular sensitivity directly.

A blood DHT level seems like the obvious next test, and it's usually not a useful one. Serum DHT reflects conversion happening throughout the body, not conversion happening locally at your follicle, so it doesn't tell you what the follicle itself is actually exposed to. And even a genuinely elevated follicular DHT level wouldn't answer the more important question, since it's the androgen receptor's sensitivity, not the DHT concentration in front of it, that determines whether a given follicle responds. A normal serum DHT doesn't rule out androgen-driven thinning, and an elevated one doesn't confirm it either. A scalp exam, sometimes with trichoscopy, is what actually distinguishes a diffuse process from a patterned one, information no blood panel can give you.

A Familiar Pattern

A patient in her late forties started testosterone therapy for low energy and low libido, both of which improved within weeks. Three months in, more hair on her pillow and in the shower drain had her convinced the testosterone needed to stop. Her labs told a different story: ferritin was low-normal, and her free T3 sat at the bottom of the range despite a normal TSH. Addressing both directly, alongside continuing her testosterone at the same dose, resolved the shedding over the following months without giving up the benefits she'd already gained.

What Treatment Looks Like Once the Cause Is Clear

Options aren't mutually exclusive and depend on what's actually driving it. Minoxidil remains the best-studied starting point, and pairing it with microneedling improves on minoxidil alone (Ahmed KMA et al., 2025, PMID: 40056230). PRP scalp injections show modest but real improvements in density (de Oliveira AFQ et al., 2023, PMID: 36264022). Spironolactone, finasteride, and dutasteride block androgen activity at different points and are used off-label for female pattern hair loss; finasteride and dutasteride carry a pregnancy contraindication for any woman who could become pregnant, not only those currently trying. Nutraceutical blends like Nutrafol have randomized, placebo-controlled support for improved growth in women with thinning hair (Ablon G, Kogan S, 2018). Topical exosome application after microneedling, never injected, is a newer option with encouraging early evidence that's still developing (Wan J et al., 2025, PMID: 40146273; Gupta AK et al., 2023, PMID: 37381168).

Who Should Have This Conversation

This applies to you if hair thinning started or worsened after beginning hormone therapy, if you've been told to simply lower your dose without anyone checking thyroid, ferritin, or stress load first, or if your results seem to differ from what a friend on a similar regimen describes.

What a Realistic Timeline Looks Like

Diffuse shedding from a corrected cause typically starts improving within two to three months, matching the hair cycle's own timeline, with regrowth visible several months beyond that. Androgen-directed treatments, minoxidil, PRP, spironolactone, or a 5-alpha-reductase inhibitor, generally need four to six months of consistent use before a fair assessment, with periodic monitoring built in for any prescription option.

If you're already a patient at one of my clinics, bring this up with your care team at your next visit rather than adjusting your dose on your own. If you'd like an in-clinic consultation, here are all of the practices I see patients in. Prefer to start with a question first? Reach out directly by email or Instagram.

View My Clinic Locations

Or email drwilcox@precisionhormoneconsulting.com · DM @wellnessdoc_4everyoung on Instagram

Darrell Wilcox, MD · @wellnessdoc_4everyoung on Instagram

References

  1. Hillmer AM et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. American Journal of Human Genetics. 2005. PMID: 15902657. (Study population: men with early-onset pattern baldness; cited for AR gene biology applicable to the same receptor in women, not as female-specific data.)
  2. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R. Variants in the 5α-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. Journal of Clinical Endocrinology & Metabolism. 2006;91(10):4085–4091. PMID: 16849416.
  3. Redler S et al. Selected variants of the steroid-5α-reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: no association with female pattern hair loss identified. Experimental Dermatology. 2012. PMID: 22509838.
  4. de Oliveira AFQ, Arcanjo FPN, Rodrigues MRP, Rosa e Silva AA, Hall PR. Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis. Journal of Dermatological Treatment. 2023;34(1). PMID: 36264022.
  5. Ahmed KMA, Kozaa YA, Abuawwad MT, et al. Evaluating the efficacy and safety of combined microneedling therapy versus topical minoxidil in androgenetic alopecia: a systematic review and meta-analysis. Archives of Dermatological Research. 2025;317:528. PMID: 40056230.
  6. Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. Journal of Drugs in Dermatology. 2018;17(5):558.
  7. Wan J, Kim SB, Cartier H, Garson S, Frank K, Haykal D, Yi KH. A prospective study of exosome therapy for androgenetic alopecia. Aesthetic Plastic Surgery. 2025;49(11):3151–3156. PMID: 40146273.
  8. Gupta AK, Wang T, Rapaport JA. Systematic review of exosome treatment in hair restoration: preliminary evidence, safety, and future directions. Journal of Cosmetic Dermatology. 2023;22(9):2424–2433. PMID: 37381168.

Related

This content is for educational purposes only and does not constitute medical advice. Hair loss has multiple possible causes, and an accurate diagnosis requires individualized lab evaluation and clinical exam. Finasteride and dutasteride, in any form, are contraindicated in pregnancy due to demonstrated fetal risk and require individualized discussion for any woman who could become pregnant. Spironolactone, finasteride, and dutasteride are used off-label for female pattern hair loss and require physician supervision and monitoring. Topical exosome treatments are applied topically only, not injected, and evidence for their use in hair restoration is still developing. Individual results vary, and no outcome is guaranteed. Dr. Wilcox is licensed to practice in multiple states. See About for current licensure.